| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Lyn M Moi. Lymphangioleiomyomatosis: Current understanding and potential treatments. Pharmacology & therapeutics. vol 158. 2016-10-26. PMID:26713679. |
these processes include mutational inactivation of the tuberous sclerosis complex genes, tsc1 and tsc2, activation of the mammalian target of rapamycin (mtor) pathway, enhanced cell proliferation and migration, lymphangiogenesis, metastatic spread through the blood and lymphatic circulations, sex steroid sensitivity and dysregulated autophagy. |
2016-10-26 |
2023-08-13 |
Not clear |
| Boh-Ram Kim, Seung-Hoon Lee, Mi-Sun Park, Seung-Hee Seo, Young-Min Park, Young-Joo Kwon, Seung-Bae Rh. MARCKSL1 exhibits anti-angiogenic effects through suppression of VEGFR-2-dependent Akt/PDK-1/mTOR phosphorylation. Oncology reports. vol 35. issue 2. 2016-10-17. PMID:26555156. |
consistently, marcksl1 decreased vegf‑induced phosphorylation of the pi3k/akt signaling pathway components, including phosphoinositide-dependent protein kinase 1 (pdk-1), mammalian target of rapamycin (mtor), tuberous sclerosis complex 2 (tsc-2), p70 ribosomal protein s6 kinase (p70s6k), and glycogen synthase kinase 3β (gsk-3β) protein. |
2016-10-17 |
2023-08-13 |
human |
| Rimas V Lukas, Derek A Wainwright, John J Laterr. Updates from the Neuro-Oncology Section of the 2015 American Neurological Association Annual Meeting. Future oncology (London, England). vol 12. issue 2. 2016-10-13. PMID:26616737. |
the recent success of targeting the mtor pathway in the neurocutaneous syndrome tuberous sclerosis is detailed. |
2016-10-13 |
2023-08-13 |
Not clear |
| Yu Gao, Ronald B Gartenhaus, Rena G Lapidus, Arif Hussain, Yanting Zhang, Xinghuan Wang, Han C Da. Differential IKK/NF-κB Activity Is Mediated by TSC2 through mTORC1 in PTEN-Null Prostate Cancer and Tuberous Sclerosis Complex Tumor Cells. Molecular cancer research : MCR. vol 13. issue 12. 2016-10-05. PMID:26374334. |
it has been reported that akt activates mtor through phosphorylation and inhibition of the tuberous sclerosis complex (tsc) protein tsc2. |
2016-10-05 |
2023-08-13 |
Not clear |
| b' Aristea S Galanopoulou, Solomon L Mosh\\xc3\\xa. Neonatal and Infantile Epilepsy: Acquired and Genetic Models. Cold Spring Harbor perspectives in medicine. vol 6. issue 1. 2016-10-05. PMID:26637437.' |
potentially pathogenic mechanisms in these conditions include interneuronopathies in is or dravet syndrome and mtor dysregulation in brain malformations, tuberous sclerosis, and related genetic disorders, or is of acquired etiology. |
2016-10-05 |
2023-08-13 |
Not clear |
| Marni E Harris-White, Kathie G Ferbas, Ming F Johnson, Pirooz Eslami, Aleksandra Poteshkina, Kalina Venkova, Alexandar Christov, Kenneth Hensle. A cell-penetrating ester of the neural metabolite lanthionine ketimine stimulates autophagy through the mTORC1 pathway: Evidence for a mechanism of action with pharmacological implications for neurodegenerative pathologies. Neurobiology of disease. vol 84. 2016-09-26. PMID:25779968. |
the lke site of action was near mtor because neither lke nor the mtor inhibitor rapamycin affected tuberous sclerosis complex (tsc) phosphorylation status upstream from mtor. |
2016-09-26 |
2023-08-13 |
mouse |
| Manabu Taneike, Kazuhiko Nishida, Shigemiki Omiya, Elham Zarrinpashneh, Tomofumi Misaka, Rika Kitazume-Taneike, Ruth Austin, Minoru Takaoka, Osamu Yamaguchi, Michael J Gambello, Ajay M Shah, Kinya Ots. mTOR Hyperactivation by Ablation of Tuberous Sclerosis Complex 2 in the Mouse Heart Induces Cardiac Dysfunction with the Increased Number of Small Mitochondria Mediated through the Down-Regulation of Autophagy. PloS one. vol 11. issue 3. 2016-08-29. PMID:27023784. |
mtor hyperactivation by ablation of tuberous sclerosis complex 2 in the mouse heart induces cardiac dysfunction with the increased number of small mitochondria mediated through the down-regulation of autophagy. |
2016-08-29 |
2023-08-13 |
mouse |
| Aglaya G Iyevleva, Evgeny N Imyanito. Cytotoxic and targeted therapy for hereditary cancers. Hereditary cancer in clinical practice. vol 14. issue 1. 2016-08-24. PMID:27555886. |
ret inhibitors for hereditary medullary thyroid cancer, mtor inhibitors for tumors arising in patients with tuberous sclerosis (tsc), and smo inhibitors for basal-cell nevus syndrome. |
2016-08-24 |
2023-08-13 |
Not clear |
| Jeffrey P MacKeigan, Darcy A Kruege. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex. Neuro-oncology. vol 17. issue 12. 2016-08-22. PMID:26289591. |
differentiating the mtor inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex. |
2016-08-22 |
2023-08-13 |
Not clear |
| Małgorzata Sobieck. [Lymphangioleiomyomatosis - new concepts on pathogenesis, diagnosis and treatment]. Wiadomosci lekarskie (Warsaw, Poland : 1960). vol 69. issue 2 Pt 1. 2016-08-22. PMID:27421126. |
lam, affecting almost exclusively women, is associated with inactivating tuberous sclerosis complex (tsc) gene mutations in lam cells, resulting in activation of mtor that controls cell proliferation, growth and motility. |
2016-08-22 |
2023-08-13 |
Not clear |
| Maria M Alves, Gwenny M Fuhler, Karla C S Queiroz, Jetse Scholma, Susan Goorden, Jasper Anink, C Arnold Spek, Marianne Hoogeveen-Westerveld, Marco J Bruno, Mark Nellist, Ype Elgersma, Eleonora Aronica, Maikel P Peppelenbosc. PAK2 is an effector of TSC1/2 signaling independent of mTOR and a potential therapeutic target for Tuberous Sclerosis Complex. Scientific reports. vol 5. 2016-08-19. PMID:26412398. |
pak2 is an effector of tsc1/2 signaling independent of mtor and a potential therapeutic target for tuberous sclerosis complex. |
2016-08-19 |
2023-08-13 |
mouse |
| John J Bissler, John Christopher Kingswood, Elżbieta Radzikowska, Bernard A Zonnenberg, Michael Frost, Elena Belousova, Matthias Sauter, Norio Nonomura, Susanne Brakemeier, Petrus J de Vries, Noah Berkowitz, Sara Miao, Scott Segal, Severine Peyrard, Klemens Budd. Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. vol 31. issue 1. 2016-08-16. PMID:26156073. |
mammalian target of rapamycin (mtor) inhibitors are recommended as first-line treatment of renal angiomyolipoma associated with tuberous sclerosis complex (tsc) or sporadic lymphangioleiomyomatosis (sporadic lam), but follow-up is limited. |
2016-08-16 |
2023-08-13 |
Not clear |
| Bo Kong, Weiwei Wu, Tao Cheng, Anna Melissa Schlitter, Chengjia Qian, Philipp Bruns, Ziying Jian, Carsten Jäger, Ivonne Regel, Susanne Raulefs, Nora Behler, Martin Irmler, Johannes Beckers, Helmut Friess, Mert Erkan, Jens T Siveke, Andrea Tannapfel, Stephan A Hahn, Fabian J Theis, Irene Esposito, Jörg Kleeff, Christoph W Michalsk. A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling. Gut. vol 65. issue 4. 2016-07-18. PMID:25601637. |
oncogenic kras-activated robust mek/erk signals phosphorylate to the tuberous sclerosis complex (tsc) and deactivates mammalian target of rapamycin (mtor) suppression in pancreatic ductal adenocarcinoma (pdac); however, mek and mtor inhibitors alone have demonstrated minimal clinical antitumor activity. |
2016-07-18 |
2023-08-13 |
Not clear |
| Zhao Zhong Chon. mTOR: A Novel Therapeutic Target for Diseases of Multiple Systems. Current drug targets. vol 16. issue 10. 2016-07-13. PMID:25850623. |
mtor is activated by phosphorylation and functions mainly through mtor complex 1 or mtor complex 2. mtorc1 is activated through tuberous sclerosis complex 1/2 dependent and independent mechanisms following the stimulation by growth factors, nutrient, amino acids, and other signaling pathways. |
2016-07-13 |
2023-08-13 |
Not clear |
| Yang Zhao, Ming-Ming Zhao, Yan Cai, Ming-Fei Zheng, Wei-Liang Sun, Song-Yang Zhang, Wei Kong, Jun Gu, Xian Wang, Ming-Jiang X. Mammalian target of rapamycin signaling inhibition ameliorates vascular calcification via Klotho upregulation. Kidney international. vol 88. issue 4. 2016-07-13. PMID:26061549. |
when mtor signaling was enhanced by either mtor overexpression or deletion of tuberous sclerosis 1, klotho mrna was further decreased in phosphate-treated vsmcs, suggesting a vital association between mtor signaling and klotho expression. |
2016-07-13 |
2023-08-13 |
mouse |
| Ning Liang, Mario Pend. YAP enters the mTOR pathway to promote tuberous sclerosis complex. Molecular & cellular oncology. vol 2. issue 4. 2016-06-16. PMID:27308518. |
yap enters the mtor pathway to promote tuberous sclerosis complex. |
2016-06-16 |
2023-08-13 |
Not clear |
| Benjamin E Housden, Alexander J Valvezan, Colleen Kelley, Richelle Sopko, Yanhui Hu, Charles Roesel, Shuailiang Lin, Michael Buckner, Rong Tao, Bahar Yilmazel, Stephanie E Mohr, Brendan D Manning, Norbert Perrimo. Identification of potential drug targets for tuberous sclerosis complex by synthetic screens combining CRISPR-based knockouts with RNAi. Science signaling. vol 8. issue 393. 2016-06-06. PMID:26350902. |
the tuberous sclerosis complex (tsc) family of tumor suppressors, tsc1 and tsc2, function together in an evolutionarily conserved protein complex that is a point of convergence for major cell signaling pathways that regulate mtor complex 1 (mtorc1). |
2016-06-06 |
2023-08-13 |
human |
| Rajalaxmi Natarajan, Kara Barber, Amanda Buckley, Phillip Cho, Anuoluwapo Egbejimi, Yogesh P Wairka. Tricornered Kinase Regulates Synapse Development by Regulating the Levels of Wiskott-Aldrich Syndrome Protein. PloS one. vol 10. issue 9. 2016-05-31. PMID:26393506. |
mtor, a kinase, is shared between two functionally distinct multi-protein complexes- mtorc1 and mtorc2, that act downstream of tuberous sclerosis complex (tsc). |
2016-05-31 |
2023-08-13 |
drosophila_melanogaster |
| Oak Z Chi, Chang-Chih Wu, Xia Liu, Kang H Rah, Estela Jacinto, Harvey R Weis. Restoration of Normal Cerebral Oxygen Consumption with Rapamycin Treatment in a Rat Model of Autism-Tuberous Sclerosis. Neuromolecular medicine. vol 17. issue 3. 2016-05-20. PMID:26048361. |
tuberous sclerosis (tsc) is associated with autism spectrum disorders and has been linked to metabolic dysfunction and unrestrained signaling of the mammalian target of rapamycin (mtor). |
2016-05-20 |
2023-08-13 |
rat |
| Xinxin Ci, Masayuki Kuraoka, Hongxia Wang, Zachary Carico, Kristen Hopper, Jinwook Shin, Xuming Deng, Yirong Qiu, Shyam Unniraman, Garnett Kelsoe, Xiao-Ping Zhon. TSC1 Promotes B Cell Maturation but Is Dispensable for Germinal Center Formation. PloS one. vol 10. issue 5. 2016-04-21. PMID:26000908. |
accumulating evidence indicates that the tuberous sclerosis complex 1 (tsc1), a tumor suppressor that acts by inhibiting mtor signaling, plays an important role in the immune system. |
2016-04-21 |
2023-08-13 |
mouse |